The latest announcement is out from C4 Therapeutics (CCCC).
C4 Therapeutics, Inc. has partnered with Merck KGaA in a significant deal to advance cancer treatment, focusing on the development of two targeted protein degraders. The collaboration could yield C4T up to $740 million, plus royalties from sales, while Merck KGaA will cover all costs from development to commercialization. This strategic partnership marks a notable stride in oncology research and offers potential financial windfalls for both companies as they work towards breakthroughs in cancer therapy.
Learn more about CCCC stock on TipRanks’ Stock Analysis page.
